olfactory receptor family 52 subfamily H member 2 pseudogeneGenealiases: []
Q-omics provides the consensus-scored OR52H2P profile across patient tissues and cancer cell-line models. OR52H2P expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, OR52H2P is differentially expressed in 2, with the highest sampling consensus in LUSC. Additionally, OR52H2P RNA expression shows 10,468 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UCS, LUSC, and LSCC as cancer lineages where OR52H2P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR52H2P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR52H2P survival associations across molecular data types. OR52H2P RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR52H2P RNA expression–survival associations across cancer types. High OR52H2P expression shows unfavorable associations in UCS, COAD, LIHC, SKCM and ACC, but favorable associations in OV. The UCS Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify UCS as the clearest survival context for OR52H2P RNA expression.
This table summarizes OR52H2P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for OR52H2P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR52H2P shows lower tumor expression in LUSC and higher tumor expression in KIRC. The LUSC box plot shows higher OR52H2P RNA expression in normal versus tumor tissue (log2 FC = −0.024, t-test p = .003).
This table shows molecular features associated with OR52H2P in patient tissues and cancer cell lines. In patient samples, OR52H2P shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
